Further structure-activity relationship studies should be carried out to develop safer and superior ANO1 inhibitors based on the structure of schisandrathera D. Nevertheless, the results of this study suggest schisandrathera D as a promising lead compound for the development of oral and prostate cancer therapeutic targets which act by targeting ANO1. This evidence concerns the gene ANO1 and prostate carcinoma.